Patents Represented by Attorney Thomas C. Meyers
  • Patent number: 8209130
    Abstract: The invention relates to assembly of sequence reads. The invention provides a method for identifying a mutation in a nucleic acid involving sequencing nucleic acid to generate a plurality of sequence reads. Reads are assembled to form a contig, which is aligned to a reference. Individual reads are aligned to the contig. Mutations are identified based on the alignments to the reference and to the contig.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: June 26, 2012
    Assignee: Good Start Genetics, Inc.
    Inventors: Caleb Kennedy, Gregory J. Porreca
  • Patent number: 5503841
    Abstract: Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.
    Type: Grant
    Filed: February 24, 1989
    Date of Patent: April 2, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Michael V. Doyle, Arthur D. Newell, Jack H. Nunberg, Thomas J. White
  • Patent number: 5455330
    Abstract: Medicaments that have prophylactic or therapeutic applications for the treatment of disease resulting from the production of cytokines, particularly IL-1, that effectively inhibit the biological activity of the cytokines wherein the medicaments are characterized by being proteinaceous materials lacking a signal sequence for which a cDNA sequence has been identified and sequenced.
    Type: Grant
    Filed: June 30, 1993
    Date of Patent: October 3, 1995
    Assignee: Cetus Oncology Corporation
    Inventors: John S. Haskill, George Martin, Peter Ralph
  • Patent number: 5397703
    Abstract: The present invention relates to a method of generating antibodies directed against cell surface antigens. The method uses as immunogen recombinant insect cells into which have been transfected coding regions for a molecule containing a cell surface antigen. Host animals are immunized with these transfected insect cells to generate antibodies directed against the cell surface antigen. Antibody-producing cells from the host animal are used to generate monoclonal antibody-producing hybridoma cells. Sera and hybridoma supernatants can be tested for the presence of antibodies against the surface antigen, using the transfected cells in a screening assay.
    Type: Grant
    Filed: July 9, 1992
    Date of Patent: March 14, 1995
    Assignee: Cetus Oncology Corporation
    Inventors: Mark De Boer, Leah B. Conroy